268 related articles for article (PubMed ID: 32523133)
1. SARS-CoV-2 downregulation of ACE2 and pleiotropic effects of ACEIs/ARBs.
Ciulla MM
Hypertens Res; 2020 Sep; 43(9):985-986. PubMed ID: 32523133
[No Abstract] [Full Text] [Related]
2. The role of ACEIs/ARBs in COVID-19: Friend or foe?
Zhou Z; Qiu Y; Tao J
Med Hypotheses; 2020 Sep; 142():109810. PubMed ID: 32413701
[No Abstract] [Full Text] [Related]
3. Clinical Implications of SARS-CoV-2 Interaction With Renin Angiotensin System: JACC Review Topic of the Week.
Brojakowska A; Narula J; Shimony R; Bander J
J Am Coll Cardiol; 2020 Jun; 75(24):3085-3095. PubMed ID: 32305401
[TBL] [Abstract][Full Text] [Related]
4. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.
Vaduganathan M; Vardeny O; Michel T; McMurray JJV; Pfeffer MA; Solomon SD
N Engl J Med; 2020 Apr; 382(17):1653-1659. PubMed ID: 32227760
[No Abstract] [Full Text] [Related]
5. COVID-19 and cardiovascular disease: What we know, what we think we know, and what we need to know.
Dhawan R; Gundry RL; Brett-Major DM; Mahr C; Thiele GM; Lindsey ML; Anderson DR
J Mol Cell Cardiol; 2020 Jul; 144():12-14. PubMed ID: 32339565
[No Abstract] [Full Text] [Related]
6. Association of ACE2 receptor and ACEIs/ARBs with disease severity in COVID-19.
Sinha S; Sehgal A; Sehgal R
Drug Discov Ther; 2020; 14(4):161-170. PubMed ID: 32908071
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy.
Chung MK; Karnik S; Saef J; Bergmann C; Barnard J; Lederman MM; Tilton J; Cheng F; Harding CV; Young JB; Mehta N; Cameron SJ; McCrae KR; Schmaier AH; Smith JD; Kalra A; Gebreselassie SK; Thomas G; Hawkins ES; Svensson LG
EBioMedicine; 2020 Aug; 58():102907. PubMed ID: 32771682
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2.
Buckley LF; Cheng JWM; Desai A
J Cardiovasc Pharmacol; 2020 Jun; 75(6):526-529. PubMed ID: 32301766
[TBL] [Abstract][Full Text] [Related]
9. The interplay of hypertension, ACE-2 and SARS-CoV-2: Emerging data as the "Ariadne's thread" for the "labyrinth" of COVID-19.
Tsioufis C; Dimitriadis K; Tousoulis D
Hellenic J Cardiol; 2020; 61(1):31-33. PubMed ID: 32450334
[No Abstract] [Full Text] [Related]
10. Correlation between renin-angiotensin system and Severe Acute Respiratory Syndrome Coronavirus 2 infection: What do we know?
Vitiello A; Ferrara F
Eur J Pharmacol; 2020 Sep; 883():173373. PubMed ID: 32679185
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 receptor ACE2 gene expression and RAAS inhibitors.
Milne S; Yang CX; Timens W; Bossé Y; Sin DD
Lancet Respir Med; 2020 Jun; 8(6):e50-e51. PubMed ID: 32411576
[No Abstract] [Full Text] [Related]
12. Covid-19: the renin-angiotensin system imbalance hypothesis.
Lanza K; Perez LG; Costa LB; Cordeiro TM; Palmeira VA; Ribeiro VT; Simões E Silva AC
Clin Sci (Lond); 2020 Jun; 134(11):1259-1264. PubMed ID: 32507883
[TBL] [Abstract][Full Text] [Related]
13. The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future.
Zhang J; Wang M; Ding W; Wan J
Life Sci; 2020 Sep; 257():118142. PubMed ID: 32712300
[TBL] [Abstract][Full Text] [Related]
14. Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?
Sommerstein R; Kochen MM; Messerli FH; Gräni C
J Am Heart Assoc; 2020 Apr; 9(7):e016509. PubMed ID: 32233753
[No Abstract] [Full Text] [Related]
15. Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury.
Sarzani R; Giulietti F; Di Pentima C; Giordano P; Spannella F
Am J Physiol Lung Cell Mol Physiol; 2020 Aug; 319(2):L325-L336. PubMed ID: 32639866
[TBL] [Abstract][Full Text] [Related]
16. Severe respiratory SARS-CoV2 infection: Does ACE2 receptor matter?
Perrotta F; Matera MG; Cazzola M; Bianco A
Respir Med; 2020 Jul; 168():105996. PubMed ID: 32364961
[TBL] [Abstract][Full Text] [Related]
17. Kidney and Lung ACE2 Expression after an ACE Inhibitor or an Ang II Receptor Blocker: Implications for COVID-19.
Wysocki J; Lores E; Ye M; Soler MJ; Batlle D
J Am Soc Nephrol; 2020 Sep; 31(9):1941-1943. PubMed ID: 32669323
[No Abstract] [Full Text] [Related]
18. Focus on clinical practice: angiotensin-converting enzyme 2 and corona virus disease 2019: pathophysiology and clinical implications.
Barillà F; Bassareo PP; Calcaterra G; Romeo F; Mehta JL
J Cardiovasc Med (Hagerstown); 2020 Sep; 21(9):630-633. PubMed ID: 32740495
[TBL] [Abstract][Full Text] [Related]
19. Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients.
Rossi GP; Sanga V; Barton M
Elife; 2020 Apr; 9():. PubMed ID: 32250244
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019.
Sanchis-Gomar F; Lavie CJ; Perez-Quilis C; Henry BM; Lippi G
Mayo Clin Proc; 2020 Jun; 95(6):1222-1230. PubMed ID: 32376099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]